HC Wainwright Brokers Lower Earnings Estimates for Biodesix

Biodesix, Inc. (NASDAQ:BDSX) – Research analysts at HC Wainwright dropped their Q3 2026 earnings estimates for shares of Biodesix in a research report issued on Thursday, August 6th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.75) per share for the quarter, down from their previous estimate of ($0.74). HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Biodesix’s Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.72) EPS, Q1 2027 earnings at ($0.65) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($1.57) EPS.

A number of other equities research analysts have also weighed in on BDSX. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. Roth Capital started coverage on Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 price objective for the company. Finally, Canaccord Genuity Group increased their target price on Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.33.

Biodesix Stock Down 2.2%

Shares of Biodesix stock opened at $24.31 on Monday. Biodesix has a twelve month low of $5.26 and a twelve month high of $25.52. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. The company’s 50 day moving average is $20.02 and its 200 day moving average is $15.96. The company has a market cap of $256.47 million, a price-to-earnings ratio of -7.67 and a beta of 0.56.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The firm had revenue of $26.86 million during the quarter, compared to analyst estimates of $26.03 million.

Institutional Investors Weigh In On Biodesix

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Allworth Financial LP bought a new position in Biodesix in the 2nd quarter worth $112,000. Cetera Investment Advisers bought a new stake in Biodesix during the fourth quarter valued at about $68,000. Walleye Capital LLC bought a new stake in Biodesix during the first quarter valued at about $157,000. Thompson Davis & CO. Inc. purchased a new stake in Biodesix in the first quarter worth about $170,000. Finally, Renaissance Technologies LLC purchased a new stake in Biodesix in the first quarter worth about $173,000. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.